Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 2
---
uable upon the exercise of series C warrants, or Series C Warrants, (2) 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares issuable upon the exercise of series D warrants, or Series D Warrants and, together with the Series C Warrants, the Warrants, and (3) 4,400,000 Ordinary Shares represented by 44 Depositary Shares issuable upon the exercise of placement agent warrants issued in the Offering. On July 31, 2025, we effected a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 10,000 Ordinary Shares per Depositary Share to 100,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued. The change in the number of Depositary Shares resulting from the change in ratio has been applied retroactively to all share and per share amounts presented in this prospectus, to the extent applicable. The information included in this filing updates the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No. 2. Accordingly, this Post-Effective Amendment No. 2 concerns only the offer and sale of ordinary shares represented by Depositary Shares issuable from time to time upon exercise of such warrants that remain unexercised. All applicable registration fees were paid at the time of the original filing of the Registration Statement.

The information in this preliminary prospectus is not complete and may be changed. Neither we nor any selling shareholders may sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.

<div align='center'>PRELIMINARY PROSPECTUS—SUBJECT TO COMPLETION, DATED NOVEMBER 17, 2025

BIODEXA PHARMACEUTICALS PLC

109,800,000 Ordinary Shares Representing 1,098 American Depositary Shares</div>

This prospectus relates to the resale,
by the selling shareholders identified in this prospectus, of an aggregate of 109,800,000 ordinary shares, nominal value £0.000001
per share, or Ordinary Shares, of Biodexa Pharmaceuticals PLC, or the Company, represented by American Depositary Shares, or Depositary
Shares, issuable upon the exercise of series D warrants, or Series D